The Infectious Diseases Society of America (IDSA), the nation’s leading infectious diseases professional society, recognizes the distinguished physicians and scientists from the United States and around the world who were elected this year to be Fellows of IDSA.
In the face of new challenges to the access to testing, prevention, care and treatment necessary to stop HIV transmissions, infections, illnesses and deaths at home and globally, the theme of this year’s World AIDS Day: Ending the HIV/AIDS Epidemic: Resilience and Impact must drive the efforts ahead.
Among the nine exceptional individuals being recognized by the Infectious Diseases Society of America, James D. Cherry, M.D., FIDSA, has been honored with this year’s Alexander Fleming Award for lifetime achievement. IDSA is pleased to acknowledge the following individuals for excellence in the field of infectious diseases with its annual Society Awards:
A new evidence-based clinical practice guideline for the prevention, diagnosis and treatment of the worldwide disease caused by Babesia parasites has been published in Clinical Infectious Diseases. Providing current standards of diagnosis and management of human babesiosis, the 2020 Guideline on Diagnosis and Management of Babesiosis was developed by a multidisciplinary panel convened by IDSA.
New evidence-based clinical practice guidelines for the prevention, diagnosis, and treatment of Lyme disease have been developed by a multidisciplinary panel led by the IDSA, the American Academy of Neurology, and the American College of Rheumatology. Representatives from an additional 12 medical specialties and patients also served on the panel.
The four principles established by CDC’s Advisory Committee on Immunization Practices’ Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine set a positive course for mitigating and containing the impacts of the pandemic.
Barbara D. Alexander, M.D., MHS, FIDSA – President, Infectious Diseases Society of America on today’s Pfizer/BioNTech application for Emergency Use Authorization of its COVID-19 vaccine candidate
With numbers of infections, illnesses, hospitalizations and deaths caused by COVID-19 at record highs as this holiday season begins, the risks posed by the spread of the coronavirus are more dangerous than at any time since its emergence last December.
IDSA awarded seven institutions the designation of Antimicrobial Stewardship Center of Excellence. The designated hospitals have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
Cornelius J. Clancy, M.D., member of the Infectious Diseases Society of America’s Antimicrobial Resistance Committee, presented on behalf of IDSA at today’s Food and Drug Administration public meeting to provide feedback on an FDA concept paper regarding the ranking of antimicrobial drugs according to their importance
We share and appreciate the urgency in expanding therapeutic options for COVID-19 as daily case counts and hospitalization rates reach record levels. For new therapeutics to be used widely and routinely outside of clinical trials, we urge that there be sufficient safety and efficacy data to be confident regarding their use.
The Infectious Diseases Society of America and its HIV Medicine Association have reached out today to President-elect Joe Biden to congratulate him and to offer their memberships’ expertise as the new administration takes on the challenges of the COVID-19 pandemic and other infectious diseases threats.